Overview

• WU-CART-007 employs CRISPR to engineer donor-derived CAR-T cells that target CD7 on malignant T cells while preventing graft-versus-host disease and fratricide.
• The Phase I/II study treated 28 adults and adolescents with relapsed or refractory T cell acute lymphoblastic leukemia or lymphoblastic lymphoma across sites in the U.S., Australia and Europe.
• Of 11 evaluable participants, 10 (91%) saw significant tumor reduction and eight (72.7%) achieved complete remission.
• Cytokine release syndrome occurred in 88.5% of patients but was predominantly mild or moderate, with rare cases of severe infections, neurotoxicity and low-grade graft-versus-host disease.
• Researchers from Washington University School of Medicine and biotech firm Wugen have launched a broader international trial to validate the therapy’s safety and efficacy at scale.